Interim report
Page 1
Remedy Entertainment Plc November 3, 2026 Business Review JANUARY–SEPTEMBER 2026
Page 2
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 2 (21) Remedy Entertainment Plc | Stock exchange release | November 3, 2026, at 09:00 a.m. EET Remedy Entertainment Plc | Business Review January–September 2026 CONTROL Resonant launched, received excellent player reception and became the fastest-selling Remedy game to date Revenue tripled, positive operating profit The Business Review is unaudited. Figures in parentheses refer to the comparison period in the previous year, unless otherwise stated. Highlights from July–September 2026 • Revenue increased by 226.0% to EUR 39.6 (12.2) million. • EBITDA was EUR 6.8 (0.7) million. • Operating profit (EBIT) was EUR 0.6 (-16.4) million, and the operating profit margin was 1.5% (-135.1%) of revenue. • Cash flow from operations was EUR -0.1 (11.3) million. • On September 24, 2026, Remedy launched CONTROL Resonant worldwide. • In September 2026, the Board of Directors decided on a new option plan 2026. • After the review period, on October 15, 2026, the physical edition of CONTROL Resonant was released, and Remedy announced the game had sold over one million copies. Highlights from January–September 2026 • Revenue increased by 48.2% to EUR 62.9 (42.5) million. • EBITDA was EUR 7.3 (7.5) million. • Operating profit (EBIT) was EUR -2.3 (-15.6) million, and the operating profit margin was -3.7% (-36.7%) of revenue. • Cash flow from operations was EUR 7.5 (7.8) million. • In February 2026, Jean-Charles Gaudechon was appointed as the CEO of Remedy as of March 1, 2026.
Page 3
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 3 (21) Key Figures MEUR, IFRS, Group, unaudited 7–9/2026 7–9/2025 1–9/2026 1–9/2025 1–12/2025 Revenue 39.6 12.2 62.9 42.5 59.5 Change in revenue, % 226.0% -32.0% 48.2% 8.9% 17.5% EBITDA 6.8 0.7 7.3 7.5 11.3 EBITDA, % of revenue 17.1% 5.7% 11.6% 17.6% 19.1% Operating profit (EBIT) 0.6 -16.4 -2.3 -15.6 -14.9 Operating profit, % of revenue 1.5% -135.1% -3.7% -36.7% -25.0% Result for review period -0.1 -13.5 -2.9 -13.4 -13.0 Result for review period, % of revenue -0.3% -110.7% -4.6% -31.6% -21.9% Balance sheet total 97.1 88.0 97.1 88.0 87.5 Cash flow from operations -0.1 11.3 7.5 7.8 4.5 Net cash 6.5 19.2 6.5 19.2 11.1 Cash and liquid investments 24.1 36.5 24.1 36.5 29.4 Net gearing, % -11.9% -34.0% -11.9% -34.0% -19.7% Equity ratio, % 57.1% 68.9% 57.1% 68.9% 67.4% Capital expenditures 4.9 2.2 12.0 11.4 14.3 Average number of personnel during review period (FTE) 367 377 371 370 371 Headcount at the end of period 378 391 378 391 387 Earnings per share, € -0.01 -0.99 -0.21 -0.99 -0.96 Earnings per share, € (diluted) -0.01 -0.99 -0.21 -0.99 -0.96 Number of shares at the end of period 13,640,451* 13,640,451 13,640,451* 13,640,451 13,640,451* *Includes 50,000 treasury shares.
Page 4
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 4 (21) Comments by CEO Jean-Charles Gaudechon In the third quarter, Remedy successfully launched CONTROL Resonant’s digital version across all platforms on September 24, 2026. This is our first self-published game of this scale, built on our own CONTROL IP. Praised by players and critics alike, it marks a defining milestone for the company. Revenue for this quarter was EUR 39.6 (12.2) million, and more than tripled from the comparison period. The increase was driven by the game sales of CONTROL Resonant, including preorders and first 7 days of game sales which fell within the quarter. The majority of the quarter’s total revenue came from game sales and royalties, which amounted to EUR 35.3 (6.0) million. Development fees, originating from Max Payne 1&2 remake and the final development fee accrual for CONTROL Resonant under our agreement with Annapurna Pictures, totaled EUR 4.3 (6.1) million. As a self-publisher, we carry royalty expenses and platform fees directly. Our royalty expenses consist of Annapurna's share of CONTROL Resonant game revenue. As announced in August 2024, these royalty expenses will decrease once the initial investments have been recouped. With the launch, we began depreciating the game’s capitalized development costs, and marketing spend peaked around the launch. EBITDA was EUR 6.8 (0.7) million and operating profit (EBIT) was EUR 0.6 (-16.4) million. CONTROL Resonant CONTROL Resonant was launched in great quality to an enthusiastic player reception. On October 15, 2026, the day of the physical release, and three weeks after launch, it passed one million copies sold worldwide, making CONTROL Resonant the fastest- selling game in Remedy’s history. The game received a combined Metacritic rating of 83. Players have responded even more positively with a Metacritic user score of 8.8/10, the latest Steam user rating at 91% positive and 4.7/5 user rating on average on PlayStation 5. Ratings are based on November 2, 2026 data. Players also voted CONTROL Resonant the top new game of September 2026 in PlayStation’s Players’ Choice poll. Critics highlighted the gameplay, strong level design, artistic ambition, and Remedy’s willingness to take creative risks and surprise its players. We see the game as an excellent entry into the large action-RPG genre. We are also pleased with the game's technical performance and the positive commentary over its scalability across a variety of PC hardware which meant a larger audience could enjoy CONTROL Resonant. This is a testament to our in-house Northlight game engine, which enables the distinctive look and feel that has come to define Remedy’s games. We backed the launch with the largest marketing investment in our history. As planned, the campaign peaked in Q3, and it included many firsts for Remedy. Around the launch, we ran global digital campaigns alongside out-of-home advertising and partnered with PlayStation, NVIDIA and leading content creators. We also reached out to our growing communities in Asia and Latin America for the first time at this scale, giving local press and creators early access and bringing CONTROL Resonant to live
Page 5
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 5 (21) events. The campaign achieved global attention and was further amplified by significant organic media coverage. The United States was CONTROL Resonant’s largest market on both PC and consoles, by revenue and units alike, accounting for nearly half of all sales. On PC, Chinese-speaking regions and the United Kingdom ranked second and third, while on consoles the United States was followed by the United Kingdom and Canada. By console units, Brazil also reached the top three, reflecting the traction we have seen in growth markets since the pre-order campaign. Based on analytic data, close to 50% of players were new to CONTROL. Reaching new players was a key goal for this game, and these early result indicates a growing audience for the franchise and for Remedy. Outstanding wishlists currently stand at 2.4 million, providing a substantial potential audience for the future. Games in the market Control’s game sales in Q3 exceeded both the comparison period and the first two quarters of this year. Interest in the CONTROL franchise has been strong and consistent since CONTROL Resonant was announced in December 2025. The build-up to the launch of CONTROL Resonant, supported by promotions for the original game, gave Control a further lift. The Alan Wake franchise had a quieter quarter. Alan Wake 2’s capitalized development costs were fully depreciated during Q3. FBC: Firebreak remains available, sales mainly originating from subscription service agreements. In its second year on the market, the total revenue level is lower than earlier in the game’s life cycle. Building on solid momentum for the final quarter Our priority now is to get CONTROL Resonant into the hands of more players. Excellent player reviews, penetration in all our target markets and a substantial outstanding wishlist base give a solid foundation for the game’s longer-term sales potential, supported by both organic visibility as well as our targeted marketing activities. As with the launch, we will invest with discipline, prioritizing actions with a clear return. In the larger picture, with the sequel we have now established CONTROL as a true franchise. Alongside the launch of CONTROL Resonant, our other projects are proceeding in the pipeline. Sales over the remainder of the year will ultimately define our financial year 2026. CONTROL Resonant gives us a solid foundation for growth. Finally, a sincere thank you to everyone at Remedy and our partners. CONTROL Resonant is the result of years of dedication from the whole studio, and I am very proud of what we have achieved together.
Page 6
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 6 (21) Games in development Game Publisher Stage-gate status CONTROL Resonant Remedy Entertainment Post-launch development New project Remedy Entertainment Production readiness Max Payne 1&2 remake Rockstar Games Full production Outlook 2026 (unchanged) Remedy expects its full year revenue and EBITDA to increase from the previous year. Long-term business prospects We have two established own franchises, CONTROL and Alan Wake, which are linked through the Remedy Connected Universe. Remedy will self-publish upcoming games, in which Remedy owns the IP. Growing and expanding the two franchises will be a key part of our future. In addition, we work with a partner franchise Max Payne, originally created by Remedy. By 2030, we aim to be a highly regarded creative studio with sustainable, significant commercial success. We have set ourselves the following financial targets: 1) Double the 2024 revenue by 2027 with continued growth beyond this milestone and 2) EBITDA margin of 30% by 2027 and maintain that minimum level throughout the strategy period. Webcast Remedy will host a webcast in English on its Q3 2026 financial results for investors, analysts and media on November 3, 2026, at 12:00 p.m. (EET). Remedy’s financial results will be presented by CEO Jean-Charles Gaudechon and CFO Santtu Kallionpää. The Business Review will be available after publication on Remedy’s Investor website: https://investors.remedygames.com/financials-and-reports/financial-reports/. Webcast details: Register in advance for the webcast: https://remedy.videosync.fi/q3-2026/register After registering, you will receive a confirmation email containing information about joining the webcast.
Page 7
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 7 (21) A recording of the webcast will be available afterwards on Remedy’s Investor website: https://investors.remedygames.com/financials-and-reports/financial-reports/. More information Santtu Kallionpää, CFO Phone: +358 40 576 8060 Email: santtu.kallionpaa@remedygames.com Remedy in brief Remedy Entertainment Plc is a pioneering, globally renowned video game company founded in 1995 and headquartered in Finland with an office in Stockholm, Sweden. Known for its story-driven and visually stunning action games, Remedy has created multiple successful, critically acclaimed franchises such as CONTROL, Alan Wake and Max Payne. Remedy also develops its own Northlight game engine and tools technology that powers its games. Remedy’s shares are listed on Nasdaq Helsinki’s main list. www.remedygames.com
Page 8
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 8 (21) Result from business operations July–September 2026 In July‒September 2026, Remedy’s revenue was EUR 39.6 (12.2) million, which was EUR 27.5 million higher than in the comparison period. Game sales and royalties were EUR 35.3 (6.0) million, representing 89% of the quarter’s total revenue. The revenue increase was due to the launch of CONTROL Resonant at the end of the review period. Development fees were EUR 4.3 (6.1) million, being at a lower level than in the comparison period. Besides the CONTROL Resonant game sales, other main sources of revenue were development fees from Max Payne 1&2 remake, final development fees for CONTROL Resonant as well as game sales from Control and FBC: Firebreak, and royalties from Alan Wake games. In July‒September 2026, Remedy's EBITDA was EUR 6.8 (0.7) million and operating profit (EBIT) was EUR 0.6 (-16.4) million. Materials and services expenses, at EUR 20.0 million, were EUR 17.0 million higher than in the comparison period, mainly driven by increased royalty expenses and platform fees following the increased game sales. Personnel expenses, at EUR 5.0 million, were in total 14.6% lower than in the comparison period. The salary expenses remained at a similar level to the comparison period, while higher capitalization of development costs reduced reported personnel expenses. Depreciation and impairment expenses were EUR 6.2 million, being EUR 10.9 million lower than in the comparison period. Q3 2025 included a non-cash impairment of EUR 14.9 million related to FBC: Firebreak. Excluding the impairment, depreciation expenses increased by EUR 4.0 million, mainly due to the beginning of CONTROL Resonant related depreciation. During the reporting period the remaining capitalized development costs of Alan Wake 2 were fully depreciated. Other operating expenses, at EUR 8.0 million, increased by EUR 5.4 million as the CONTROL Resonant marketing activities accelerated around the launch of the game. January–September 2026 In January‒September 2026, Remedy’s revenue increased by 48.2% year-on-year, amounting to EUR 62.9 (42.5) million. Game sales and royalties were EUR 44.1 (18.2) million and development fees were EUR 18.9 (24.3) million. The main sources of revenue were CONTROL Resonant game sales and development fees from Max Payne 1&2 remake and CONTROL Resonant. Control game sales were also on a higher level than in the comparison period, Alan Wake 2 continued to accrue royalties and FBC: Firebreak also accumulated game sales for the reporting period. In January‒September 2026, Remedy's EBITDA was EUR 7.3 (7.5) million and operating profit (EBIT) was EUR -2.3 (-15.6) million. Materials and services expenses, at EUR 22.8 million, were EUR 13.6 million higher than in the comparison period, as the game sales related platform fees and royalty expenses to partners increased. Personnel expenses, at EUR 18.1 million, were 1.3% lower than in the comparison period. Depreciation and impairment expenses were EUR 9.6 million, being EUR 13.4 million lower than in the comparison period, due to Q3 2025 including a non-cash
Page 9
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 9 (21) impairment of EUR 14.9 million related to FBC: Firebreak. Other operating expenses, at EUR 15.1 million, increased by EUR 7.6 million from the comparison period. Cash flow and financial position Cash flow July–September 2026 In July‒September 2026, Remedy’s net cash flow was EUR -0.3 (8.8) million. The change in net cash flow was mainly driven by the changes in the cash flow from business operations. Cash flow from business operations was EUR -0.1 (11.3) million, which was affected by the timing of incoming payments. Both revenue and operating expenses grew during the reporting period compared to Q3 2025. Trade and other receivables increased, driven by game sales for which payments are expected in future periods. Trade and other payables also increased, mainly due to upcoming royalty expense and marketing-related payments. In the comparison period, cash flow from business operations included B2B payments related to FBC: Firebreak. In July‒September 2026, Remedy’s cash flow from investing activities amounted to EUR 0.2 (-2.2) million. Cash flow from investments was impacted by EUR 5.0 million liquidation of cash management investments. Payments related to capitalized development costs, at EUR 4.8 million, increased by EUR 2.7 million during the reporting period. Cash flow from financing activities amounted to EUR -0.4 (-0.4) million. January–September 2026 In January‒September 2026, Remedy’s net cash flow was EUR -0.4 (-2.2) million. Cash flow from business operations amounted to EUR 7.5 (7.8) million. The outgoing payments from business operations grew slightly more than the incoming payments from the comparison period, however the cash flow from business operations remained in total at a similar level to the comparison period. Cash flow from business operations is affected by agreed payments terms with partners as well as the timing of significant incoming development fee payments. It can therefore differ significantly during certain periods from accrual-based revenue recognized within a period. In January‒September 2026, Remedy’s cash flow from investing activities was EUR -6.8 (-8.8) million. Payments related to capitalized development costs, at EUR 11.5 million, increased by EUR 3.3 million during the reporting period. In the comparison period, the cash flow from investing activities contained also the final instalment to 505 Games EUR 3.2 million as well as liquidation of cash management investments of EUR 3.0 million. Cash flow from financing activities was EUR -1.1 (-1.2) million.
Page 10
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 10 (21) Financial position Remedy’s non-current assets on September 30, 2026, were EUR 45.4 (43.1) million in total. The amount of capitalized product development expenses increased, while tangible assets as well as right-of-use assets decreased. Remedy has capitalized development costs for several projects, as well as purchased publishing rights of the CONTROL franchise. The total amount of capitalized product development expenses was EUR 25.5 (19.7) million on September 30, 2026. The majority of the capitalized product development expenses are related to CONTROL Resonant. Other intangible assets amounted to EUR 6.3 (7.9) million and comprised of purchased CONTROL related publishing and distribution rights, of which the majority are also allocated to CONTROL Resonant. On September 30, 2026, Remedy’s cash position was EUR 9.3 (18.8) million and other current financial assets were EUR 14.8 (17.7) million. Other current financial assets include Remedy’s liquid cash management investments. Total cash and liquid investments were EUR 24.1 (36.5) million. The company’s liabilities on September 30, 2026, amounted to EUR 42.0 (31.4) million. Trade and other payables increased from Q3 2025 by EUR 10.3 million to EUR 23.3 million, mainly due to upcoming royalty expense and marketing-related payments. Liabilities also included EUR 16.1 (14.4) million relating to the convertible loan agreement entered into with Tencent in September 2024. The equity component of the convertible loan amounted to EUR 1.5 million, remaining unchanged since the beginning of the agreement. Remedy’s balance sheet total on September 30, 2026, was EUR 97.1 (88.0) million and equity EUR 55.1 (56.6) million. The company’s equity ratio was 57.1% (68.9%) and net gearing -11.9% (-34.0%). Personnel, management and governance The number of the company’s personnel (headcount) was 378 (391) at the end of the period under review, decreasing by 3.3% year-on-year. The average number of personnel (FTE) was 367 (377) during the reporting period, being down by 2.7% from the comparison period. At the end of the reporting period, the company’s Core Management Team comprised CEO Jean-Charles Gaudechon, CFO Santtu Kallionpää, Chief Product Officer Markus Mäki, Creative Director Sami Järvi, Creative Director Mikael Kasurinen, Chief Commercial Officer Johannes Paloheimo and Chief Technology Officer Mika Vehkala.
Page 11
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 11 (21) Shares, shareholders and share-based incentive schemes Remedy’s shares are traded in Nasdaq Helsinki with the trading code REMEDY. The closing price of Remedy’s shares on the last trading day of the review period was 19.20 euros. January– September 2026 Highest share price, € Lowest share price, € Closing share price, € Volume-weighted average price, € Remedy 19.88 11.10 19.20 15.10 September 30, 2026 September 30, 2025 December 31, 2025 Market capitalization, € 260,936,659 210,881,372 206,574,855 Number of shareholders 17,197 16,874 16,365 Number of shares at the end of period 13,640,451 13,640,451 13,640,451 Number of shares outstanding at the end of period 13,590,451 13,640,451 13,590,451 Average number of shares outstanding within period 13,590,451 13,610,173 13,610,679 Average number of shares outstanding within period, diluted (IFRS)* 13,599,102 13,646,313 13,637,784 Average number of shares outstanding within period, diluted 13,663,895 13,703,895 13,680,971 Value of share turnover within period 45,734,962 20,325,765 27,742,810 Total number of traded shares within period 3,029,112 1,362,297 1,883,682 *Calculated according to International Financial Reporting Standards (IFRS). The company has one series of shares (ISIN: FI4000251897). The number of shares in the company was 13,640,451 on September 30, 2026, of which Remedy held 50,000 treasury shares. Excluding the treasury shares, the number of outstanding shares at the end of period was 13,590,451. On May 21, 2026, the Annual General Meeting granted the Board of Directors an authorisation to resolve on the issuance of new shares, treasury shares and option rights or other special rights to shares in one or several instalments either against payment or without payment so that the number of shares to be issued can be at maximum 1,000,000. On September 30, 2026, 650,000 shares are left to be issued under the authorization of the Annual General Meeting on said date.
Page 12
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 12 (21) Major shareholders on September 30, 2026 Name Shares Percentage 1. Mäki Markus 2,697,000 19.8 2. Mariatorp Oy 1,126,000 8.3 3. Järvi Sami 360,000 2.6 4. Virtala Tero 235,125 1.7 5. Sijoitusrahasto Aktia Capital 188,807 1.4 6. Lehtinen Saku 180,000 1.3 7. Varma Mutual Pension Insurance Company 150,000 1.1 8. Proprius Partners Micro Finland (Non-Ucits) 123,318 0.9 9. Paloheimo Johannes 106,000 0.8 10. Pulkkinen Janne 100,000 0.7 10 largest shareholders total 5,266,250 38.6 Accendo Capital SICAV RAIF (nominee registered) 1,863,162 13.7 Other nominee registered 2,590,790 19.0 Other shares 3,870,249 28.4 Treasury shares 50,000 0.4 Total 13,640,451 100.0%
Page 13
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 13 (21) Option plans During the reporting period, Remedy has had six option plans directed to Remedy’s key persons: Option Plan 2021, Option Plan 2022, Option Plan 2023, Option Plan 2024, Option Plan 2025 and Option Plan 2026. The table below illustrates the key information about the option plans. More information about the option plans can be found on Remedy’s website at https://investors.remedygames.com/remuneration/. Key information about the option plans as of September 30, 2026 Option Plan Maximum number of option rights issued Number of allocated option rights Number of unexercised option rights Share subscription period Share subscription price, EUR Option Plan 2021 270,000 270,000 270,000 June 1, 2024 – May 31, 2027 47.09 Option Plan 2022 292,000 292,000 292,000 June 1, 2025 – May 31, 2028 26.64 Option Plan 2023 306,000 306,000 306,000 June 1, 2026 – May 31, 2029 27.31 Option Plan 2024 350,000 323,000 323,000 June 1, 2027 – May 31, 2030 19.76 Option Plan 2025 350,000 330,000 330,000 June 1, 2028 – May 31, 2031 16.66 Option Plan 2026 350,000 0 0 June 1, 2029 – May 31, 2032 16.29 On September 21, 2026, The Board of Directors of Remedy Entertainment Plc decided to adopt a new option plan “Option Plan 2026” directed to the key people as decided separately by the Board of Directors. The maximum total number of option rights issued is 350,000, entitling their holders to subscribe for a maximum of 350,000 new shares of the company or existing shares held by the company. The number of outstanding shares may increase at maximum by 350,000 shares as a result of the share subscriptions with the option rights, equalling 2.57 percent of all shares and votes in the company after the possible share subscription, if only new shares are issued in the subscription.
Page 14
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 14 (21) Risks and uncertainties The most substantial short-term risks and uncertainties are: Remedy’s game development efforts may fail if the company is unable to develop its games within set mandates, such as release schedule, quality, and budget. Additionally, the company’s games may not generate sufficient sales after their release, even if well received and of high quality, thus generating less than estimated game revenue for Remedy. Remedy has entered into long-term agreements with its partners related to game projects in development and game sales. If the company failed to satisfy key contract obligations, its partners could terminate their agreements with, or present claims to, the company. Remedy is self-publishing its games based on fully owned IPs and is in this way taking more financing risk in game development. In case the self-published games are not successful and do not generate sufficient sales, Remedy carries the risk of the games not becoming profitable. Remedy’s success depends significantly on its ability to hire, train, and retain skilled personnel. If the company fails in these areas, it will be unable to effectively conduct its business. Remedy’s business is subject to economic, market, and geopolitical conditions, which are beyond its control. Possible significant fluctuations in currencies, especially USD exchange rate, could have effects on Remedy’s profitability. The above-mentioned risks might, if they materialize, have a significant negative impact on Remedy’s business operations, result, financial position, outlook and share price. Events after the end of the reporting period After the review period, on October 15, 2026, the physical edition of CONTROL Resonant was released, and Remedy announced the game had sold over one million copies. There haven’t been any other significant events after the end of the review period.
Page 15
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 15 (21) Tables Consolidated statement of comprehensive income EUR thousand 7–9/2026 7–9/2025 1–9/2026 1–9/2025 1–12/2025 REVENUE 39,634 12,156 62,933 42,469 59,510 Development fees 4,339 6,115 18,881 24,261 32,947 Game sales and royalties 35,295 6,041 44,052 18,208 26,562 Other operating income 100 0 315 0 0 Materials and services -19,967 -3,010 -22,798 -9,230 -12,240 Game development related materials and services -1,033 -2,399 -3,091 -8,014 -10,471 Revenue related partner expenses -18,934 -611 -19,707 -1,216 -1,769 Personnel expenses -4,989 -5,842 -18,066 -18,307 -24,896 Depreciation, amortization and impairment -6,188 -17,113 -9,640 -23,068 -26,206 Other operating expenses -8,012 -2,615 -15,082 -7,453 -11,031 OPERATING PROFIT (LOSS) 579 -16,424 -2,337 -15,589 -14,863 Financial income -155 271 347 995 1,150 Financial expenses -459 -543 -1,204 -1,563 -1,991 PROFIT (LOSS) BEFORE INCOME TAXES -35 -16,696 -3,195 -16,157 -15,703 Income taxes -65 3,242 327 2,725 2,673 PROFIT (LOSS) FOR THE FINANCIAL YEAR -100 -13,454 -2,868 -13,431 -13,030 OTHER COMPREHENSIVE INCOME (EXPENSE) Items that may be subsequently reclassified to profit or loss 0 0 0 0 0 Total other comprehensive income (expense) for the financial year 0 0 0 0 0 TOTAL COMPREHENSIVE INCOME (EXPENSE) FOR THE FINANCIAL YEAR -100 -13,454 -2,868 -13,431 -13,030 PROFIT (LOSS) FOR THE FINANCIAL YEAR ATTRIBUTABLE TO OWNERS OF THE COMPANY -100 -13,454 -2,868 -13,431 -13,030 EARNINGS PER SHARE Basic earnings per share, euro -0.01 -0.99 -0.21 -0.99 -0.96 Diluted earnings per share, euro -0.01 -0.99 -0.21 -0.99 -0.96
Page 16
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 16 (21) Consolidated statement of financial position EUR thousand September 30, 2026 September 30, 2025 December 31, 2025 ASSETS NON-CURRENT ASSETS Intangible assets 31,780 27,631 27,933 Tangible assets 1,782 2,648 2,369 Right-of-use assets 2,446 3,727 3,391 Non-current receivables 758 745 751 Deferred tax assets 8,594 8,343 8,308 TOTAL NON-CURRENT ASSETS 45,359 43,094 42,752 CURRENT ASSETS Trade and other receivables 27,654 8,360 15,402 Current financial assets 14,839 17,709 19,754 Cash and cash equivalents 9,285 18,811 9,641 TOTAL CURRENT ASSETS 51,778 44,881 44,797 TOTAL ASSETS 97,137 87,975 87,548
Page 17
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 17 (21) EUR thousand September 30, 2026 September 30, 2025 December 31, 2025 EQUITY AND LIABILITIES EQUITY Share capital 80 80 80 Share premium 38 38 38 Invested non-restricted equity reserve 58,169 58,855 58,169 Retained earnings (losses) -271 11,015 11,337 Profit (loss) for the financial year -2,868 -13 431 -13,030 TOTAL EQUITY 55,148 56,556 56,594 LIABILITIES NON-CURRENT LIABILITIES Convertible bonds 15,086 13,544 14,838 Lease liabilities 1,154 2,459 2,123 Accrued expenses 972 900 0 Deferred tax liabilities 92 203 196 TOTAL NON-CURRENT LIABILITIES 17,304 17,105 17,157 CURRENT LIABILITIES Lease liabilities 1,349 1,297 1,306 Trade and other payables 23,336 13,016 12,491 TOTAL CURRENT LIABILITIES 24,685 14,314 13,797 TOTAL LIABILITIES 41,989 31,419 30,954 TOTAL EQUITY AND LIABILITIES 97,137 87,975 87,548
Page 18
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 18 (21) Condensed consolidated statement of cash flow EUR thousand 1–9/2026 1–9/2025 1–12/2025 Cash flow from operating activities 7,532 7,846 4,513 Cash flow from investing activities* -6,802 -8,847 -13,646 Cash flow from financing activities -1,085 -1,184 -2,222 Liquid assets - opening balance 9,641 20,996 20,996 Change in liquid assets -355 -2,185 -11,356 Liquid assets - closing balance 9,285 18,811 9,641 *Includes capitalized development costs in January-September 2026 EUR -11,493 (in January-September 2025 EUR -8,225) thousand.
Page 19
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 19 (21) Consolidated statement of changes in equity Changes in shareholders’ equity 1–9/2026 Share capital Share premium Invested non- restricted equity reserve Retained earnings SHARE- HOLDERS’ EQUITY TOTAL EUR thousand Balance January 1, 2026 80 38 58,169 -1,693 56,594 Comprehensive income Profit (Loss) for the financial year -2,868 -2,868 Other comprehensive income Total comprehensive income -2,868 -2,868 Transactions with owners of the company Share options granted 1,422 1,422 Total transactions with owners 1,422 1,422 BALANCE September 30, 2026 80 38 58,169 -3,139 55,148 Changes in shareholders’ equity 1–9/2025 Share capital Share premium Invested non- restricted equity reserve Retained earnings SHARE- HOLDERS’ EQUITY TOTAL EUR thousand Balance January 1, 2025 80 38 58,344 10,065 68,527 Comprehensive income Profit (Loss) for the financial year -13,431 -13,431 Other comprehensive income Total comprehensive income -13,431 -13,431 Transactions with owners of the company Share options granted 1,659 1,659 Share issue and other share subscriptions 510 510 Purchase of option rights -710 -710 Total transactions with owners 510 949 1,460 BALANCE September 30, 2025 80 38 58,855 -2,417 56,556
Page 20
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 20 (21) Notes to the Business Review January–September 2026 Revenue breakdown per quarter EUR thousand 7–9/2026 4–6/2026 1–3/2026 10–12/2025 7–9/2025 Development fees 4,339 6,353 8,189 8,687 6,115 Game sales and royalties 35,295 3,804 4,952 8,354 6,041 Total 39,634 10,157 13,141 17,041 12,156 Changes in tangible assets EUR thousand Machinery and equipment Other tangible assets Total 2026 2025 2026 2025 2026 2025 Cost Balance January 1 10,059 9,550 1,988 1,988 12,048 11,538 Additions 405 423 0 0 405 423 Balance September 30 10,464 9,972 1,988 1,988 12,452 11,960 Accumulated depreciation and impairment Balance January 1 -7,708 -6,233 -1,971 -1,947 -9,679 -8,180 Depreciation -974 -1,114 -17 -18 -991 -1,132 Balance September 30 -8,683 -7,347 -1,987 -1,965 -10,670 -9,312 Carrying amount on January 1 2,351 3,316 17 41 2,369 3,357 Carrying amount on September 30 1,781 2,625 1 23 1,782 2,648
Page 21
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 21 (21) Changes in intangible assets EUR thousand Capitalized development costs Other intangible assets Total 2026 2025 2026 2025 2026 2025 Cost Balance January 1 56,988 46,026 16,945 16,416 73,932 62,441 Additions 11,493 8,225 0 529 11,493 8,754 Balance September 30 68,481 54,250 16,945 16,945 85,426 71,195 Accumulated amortization and impairment Balance January 1 -36,819 -19,197 -9,181 -3,430 -45,999 -22,626 Amortization -6,155 -4,765 -1,491 -1,254 -7,647 -6,019 Impairment losses 0 -10,563 0 -4,357 0 -14,919 Balance September 30 -42,974 -34,524 -10,672 -9,040 -53,646 -43,564 Carrying amount on January 1 20,169 26,829 7,764 12,986 27,933 39,815 Carrying amount on September 30 25,507 19,726 6,273 7,905 31,780 27,631 Calculation formulas used for the indicators EBITDA: Operating profit (EBIT) + Depreciation, amortization and impairment Operating profit (EBIT): Profit (loss) before taxes and financial items Operating profit, % of revenue: Operating profit (EBIT) / revenue Net cash: Cash in hand and banks + liquid investments* - interest-bearing liabilities Net gearing, %: (Interest-bearing liabilities - cash in hand and at banks – liquid investments*) / shareholders’ equity Equity ratio, %: Shareholders’ equity / (balance sheet total - advances received) Capital Expenditures: Change in tangible and intangible assets added by depreciation of these assets *Liquid investments include Remedy’s liquid investments to equity funds. All of these investments are in cash, money market, or fixed income instruments. Espoo, November 3, 2026 Remedy Entertainment Plc Board of Directors This is not an interim report as defined in IAS 34. Remedy follows the half-year reporting schedule according to Finnish Securities Market Act and publishes business reviews off the first three and nine months of the fiscal year. These business reviews will include the most essential information regarding the company’s financial performance. The financial figures presented in this business review are unaudited.